Opus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trial
RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2026 Opus Genetics, Inc. has completed patient enrollment in its registrational Phase 3...
Vision Restoration
Advertisement
Opus Genetics Secures FDA Alignment for Phase 3 Trial
RESEARCH TRIANGLE PARK, N.C., July 6, 2026 Opus Genetics announced that the U.S. Food and Drug Administration (FDA) has...
Nanoscope Therapeutics Highlights MCO-010 Vision Data at ASGCT 2026
DALLAS, May 11, 2026 Nanoscope Therapeutics announced multiple scientific presentations at the American Society of Gene and Cell Therapy...
Beacon Therapeutics Reports Positive XLRP Gene Therapy Data
LONDON and CAMBRIDGE, Mass., May 7, 2026 Beacon Therapeutics announced encouraging 12-month safety and efficacy results from its ongoing...
Kiora Raises $24M to Advance Retinal Therapies
ENCINITAS, California, United States, April 7, 2026 Kiora Pharmaceuticals, Inc. announced the successful completion of a private placement financing...
Advertisements
Kodiak’s KSI-101 Delivers Promising Data in Retinal Disease Study
PALO ALTO, Calif., Sept. 15, 2025 – Kodiak Sciences Inc. (Nasdaq: KOD), a retina-focused biotechnology company, announced new data...
Advertisement
